

Figure Legends


Supplementary Figure 1. Patient flow in cost analysis using the JMDC Claims Database

The medical cost for TRD patients was calculated with the use of the JMDC Claims Database provided by JMDC Inc. Medical cost was calculated on the 4,211 TRD patients selected for this analysis using the inclusion/exclusion criteria from the 245,871 patients diagnosed as having depression between July 2016 and June 2019.


Supplementary Figure 2. Results of analysis at varying amounts reimbursed for each session of rTMS therapy

ICER was ¥1,428,627 (\$10,428)/QALY when the price for rTMS therapy used in the study by Nguyen et al. (150AUD: ¥14,286) was adopted into this model. ICER was ¥4,650,374 (\$33,944)/QALY when the prices for rTMS therapy used in the study by Voigt et al. (first session \$367: ¥50,279, second and subsequent sessions \$206: ¥28,222) were adopted. Reimbursement price for one session of rTMS therapy was identified to be ¥30,800 (\$225) at the ICER threshold of ¥5 million/QALY.

Supplementary Figure 1. Patient flow in cost analysis using the JMDC Claims Database



Supplementary Figure 2. Results of analysis at varying amounts reimbursed for each session of rTMS therapy



Supplementary Table 1. Summary of cost analysis using the JMDC Claims Database

Variable	Definition
Study period	July 2016 to June 2019
Index date	Secondary treatment starting date (date of antidepressant prescription within 30 days after the end of first treatment)
Follow-up period	From the index date for each patient to the last day with the record on the JMDC database
Duration of treatment	From the date of estimated last intake of antidepressant or the drug for augmentation therapy (date of prescription + number of days covered by prescription) to a point of time by which 31 days or more were without identifiable prescription of these drugs
Patients studied	
Inclusion	Diagnosed as having depression during the study period (Supplementary Table 2) and having begun to receive antidepressant treatment defined in Supplementary Table 3 after the diagnosis Having received secondary treatment within 30 days after the date of the last prescription for the primary treatment + the number of days covered by prescription (estimated date of last drug intake) Having received prescription of any of the psychotropics defined in Supplementary Table 3 or being admitted to a psychiatric ward during the follow-up period
Exclusion	Having been diagnosed as having severe depressive episode, mania, schizophrenia, epilepsy, convulsive attack, intracranial lesion, etc. accompanied by psychotic symptoms before the index date Having received medical procedure using a metallic or other device or any other material applied to the head or within 30 cm from the head during the follow-up period Having been diagnosed as being pregnant during the follow-up period
Data collected	The data on the following costs were collected during the treatment continued period
Drug costs at each treatment step	Calculated by averaging (weighted by the percentage of each drug prescribed) of the daily prescribed quantity of antidepressant or drug for augmentation therapy at each treatment line x drug price x monthly frequency of dosing
Inpatient care costs	Monthly costs of inpatient care after admission for a reason of depression
Outpatient care costs	Costs of outpatient care accompanied by prescription of antidepressant or drug for augmentation therapy
Outpatient test costs	Costs of tests conducted during outpatient visit accompanied by prescription of antidepressant or drug for augmentation therapy
ECT costs	Monthly costs of ECT applied to inpatients (192 cases) admitted after diagnosis of depression

Supplementary Table 2. Definition of depression

Variable	Definition	
	ICD10 code	ICD10 name
Moderate or severer depressive episode	F321	Moderate depressive episode
	F322	Severe depressive episode without psychotic symptoms
Moderate or severer recurrent depressive disorder	F331	Recurrent depressive disorder, current episode moderate
	F332	Recurrent depressive disorder, current severe episode without psychotic symptoms
Depressive episode, unspecified	F329	Depressive episode, unspecified
Recurrent depressive disorder, unspecified	F339	Recurrent depressive disorder, unspecified

Supplementary Table 3. Definition of antidepressants/psychotropics

Classification	Active Ingredient
Antidepressants	
Tricyclic antidepressants	Amitriptyline hydrochloride Amoxapine Imipramine hydrochloride Clomipramine hydrochloride Dosulepin hydrochloride Trimipramine maleate Nortriptyline hydrochloride Lofepramine hydrochloride
Tetracyclic antidepressants	Setiptiline maleate Maprotiline hydrochloride Mianserin hydrochloride
SSRI	Escitalopram oxalate Sertraline hydrochloride Paroxetine hydrochloride Fluvoxamine maleate
SNRI	Duloxetine hydrochloride Milnacipran hydrochloride Venlafaxine hydrochloride
SARI	Trazodone hydrochloride
Serotonin reuptake inhibitors/serotonin receptor modulators	Vortioxetine hydrobromide
NaSSA	Mirtazapine
Psychotropics	
Tricyclic antidepressants	Amitriptyline hydrochloride Amoxapine Imipramine hydrochloride Clomipramine hydrochloride Dosulepin hydrochloride Trimipramine maleate Nortriptyline hydrochloride Lofepramine hydrochloride
Tetracyclic antidepressants	Setiptiline maleate Maprotiline hydrochloride Mianserin hydrochloride
SARI	Trazodone hydrochloride
Lithium	Lithium carbonate
T3/T4 preparations	Levothyroxine sodium Dry thyroid Liothyronine sodium
Aripiprazole	Aripiprazole
Quetiapine	Quetiapine fumarate
Olanzapine	Olanzapine
Risperidone	Risperidone

Supplementary Table 4. List of parameters used for scenario analysis

Parameter	Scenario analysis value	Source
1) rTMS therapy continued as Step 2 maintenance phase treatment		
Relapse rate in Step 2 maintenance phase treatment with rTMS therapy	9.1%/year	(Haesebaert et al., 2018)
Recurrence rate in Step 2 maintenance phase treatment with rTMS therapy	24.2%/year	(Wang et al., 2017)
Cost of Step 2 maintenance phase treatment with rTMS therapy	¥69,379 (\$506)/month	JMDC Claims Database, Expert opinion
2) rTMS therapy applied as Step 3 acute phase treatment upon recurrence following Step 2 rTMS therapy		
Response rate in Step 3 acute phase treatment with rTMS therapy	84.2%/month	(Janicak et al., 2010)
Remission rate in Step 3 acute phase treatment with rTMS therapy	35.8%/month	(Sackeim et al., 2020)
Relapse rate after to Step 3 acute phase treatment with rTMS therapy	24.2%/year	(Wang et al., 2017)
Recurrence rate after Step 3 acute phase treatment with rTMS therapy	24.2%/year	(Wang et al., 2017)
Cost of Step 3 acute phase treatment with rTMS therapy	¥370,892 (\$2,707)/month	JMDC Claims Database, Expert opinion
3) rTMS therapy plus antidepressant treatment applied as Step 2 acute phase treatment		
Response rate in Step 2 acute phase treatment with rTMS plus antidepressant treatment	68.9%/month	(Sackeim et al., 2020)
Remission rate in Step 2 acute phase treatment with rTMS plus antidepressant treatment	35.8%/month	(Sackeim et al., 2020)
Relapse rate after Step 2 acute phase treatment with rTMS plus antidepressant treatment	15.9%/year	(Wang et al., 2017)
Recurrence rate after Step 2 acute phase treatment with rTMS plus antidepressant treatment	15.9%/year	(Wang et al., 2017)
Cost of Step 2 acute phase treatment with rTMS plus antidepressant treatment	¥384,975 (\$2,810)/month	JMDC Claims Database, Expert opinion
4) Productivity loss due to depression taken into consideration		
Employment rate among patients with depression	60.40%	(Statistics Bureau of Japan, 2021)
During outpatient treatment		
Absenteeism	14.10%	(Yamabe et al., 2019)
Presenteeism	42.70%	(Yamabe et al., 2019)
During inpatient treatment		
Absenteeism	100%	Assumption
Presenteeism	100%	Assumption
Mean wage (annual)		
40-44 years	¥5,323,700 (\$38,859)	
45-49 years	¥5,552,900 (\$40,532)	
50-54 years	¥5,887,100 (\$42,972)	
55-59 years	¥5,807,500 (\$42,391)	
60-64 years	¥4,356,100 (\$31,796)	
65-69 years	¥3,615,700 (\$26,392)	
70 years or older	¥3,264,100 (\$23,826)	(Ministry of Health, Labour and Welfare of Japan, 2021b)